Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534881 · ClinicalTrials.gov registry record · Phase 2
Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
A Phase 2 study, sponsored by St. Louis University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04534881 is a Phase 2 study that was terminated before completion, run by St. Louis University. The registered enrollment target is 5 participants.
The verdict
NCT04534881, a Phase 2 study, was terminated before completion, sponsored by St. Louis University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
* Purpose. The purpose of this research is study the effect of progesterone therapy on testosterone levels in transwomen who are currently on gender affirming treatment with estradiol. * Duration. It is expected that participation will last for 6 months (24 weeks). * Study Procedures. Participants will be asked to sign an informed consent, complete a medical history, have a physical exam conducted, have a fasting blood sample taken and asked to take a study drug once daily. * Risks. Some of the foreseeable risks or discomforts include temporary discomfort, bleeding, bruising and/or swelling in the arm from blood draw. There are no known direct risks with the use of Progesterone in Transwomen for gender affirming therapy. * Benefits. Some of the possible benefits that may be expected include increase in fat mass, increase in breast size/fullness, decrease in masculine hair patterns.
Interventions
- DRUG Placebo
- DRUG Progesterone 200 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04534881
The ClinicalTrials.gov registry entry for NCT04534881 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04534881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04534881 about?
NCT04534881 is a clinical study titled "Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen". * Purpose. The purpose of this research is study the effect of progesterone therapy on testosterone levels in transwomen who are currently on gender affirming treatment with estradiol. * Duration. It is expected that participation will last for 6 months (24 weeks). * Study Procedures. Participants w...
What is the current status of trial NCT04534881?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-10-20. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT04534881?
The interventions under investigation include: Placebo (DRUG), Progesterone 200 MG (DRUG).
Who is sponsoring clinical trial NCT04534881?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.